State of Wyoming Sells 16,142 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

State of Wyoming lowered its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 65.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,366 shares of the company’s stock after selling 16,142 shares during the period. State of Wyoming’s holdings in Teva Pharmaceutical Industries were worth $252,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of TEVA. Aster Capital Management DIFC Ltd bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $25,000. Cornerstone Planning Group LLC increased its stake in shares of Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after buying an additional 755 shares during the period. Allworth Financial LP increased its stake in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its position in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on TEVA shares. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Bank of America boosted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Truist Financial increased their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. UBS Group boosted their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Finally, Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.00.

Teva Pharmaceutical Industries Stock Up 9.1%

Shares of Teva Pharmaceutical Industries stock opened at $34.55 on Thursday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $14.99 and a 1 year high of $37.35. The firm has a market cap of $39.73 billion, a price-to-earnings ratio of 25.98, a PEG ratio of 3.35 and a beta of 0.86. The company has a 50-day moving average of $33.19 and a 200 day moving average of $32.69. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The business had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the sale, the executive vice president directly owned 55,755 shares of the company’s stock, valued at $1,973,727. The trade was a 34.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the transaction, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at approximately $720,576. This trade represents a 34.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 444,673 shares of company stock valued at $15,582,369 over the last ninety days. Company insiders own 0.54% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Innovative medicines delivered strong growth. Teva said its key innovative brands grew 43% year over year in local-currency terms to more than $1 billion in second-quarter revenue. The company raised its 2026 outlook for all three key brands, supporting its strategy of shifting beyond lower-margin generics. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: UZEDY momentum was particularly encouraging. U.S. sales of the long-acting schizophrenia treatment reached a record $77 million, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million previously. UZEDY Record Q2 Net Sales and Outlook
• Positive Sentiment: Revenue guidance exceeded expectations. Teva forecast 2026 revenue of $16.5 billion-$16.9 billion, broadly aligned with the $16.7 billion consensus but described by investors as better than expected. Piper Sandler also raised its price target to $44 from $42 and maintained an Overweight rating. Teva Stock Rises After Earnings
• Neutral Sentiment: Options activity reflected increased bullish interest. Traders purchased 23,688 call options, approximately 136% above typical daily call volume. This may amplify short-term momentum, but it is not a fundamental indicator of business performance.
• Negative Sentiment: Quarterly profitability fell short. Teva reported second-quarter EPS of $0.02, below the $0.08 consensus and down from $0.66 a year earlier. Revenue of $4.14 billion exceeded estimates of $4.02 billion but declined roughly 1% year over year, primarily because of weaker generics revenue. Teva Quarterly Earnings Report
• Negative Sentiment: EPS guidance was below Wall Street expectations. Teva projected 2026 EPS of $1.91-$2.11 versus the $2.17 consensus, creating a counterweight to the improved revenue outlook and strong branded-drug performance.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.